Format

Send to

Choose Destination
Anticancer Res. 2019 Oct;39(10):5353-5359. doi: 10.21873/anticanres.13728.

ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer.

Author information

1
Institute of Biomedicine, University of Turku, Turku, Finland.
2
Department of Urology, Turku University Hospital, Turku, Finland.
3
Department of Surgery, Satakunta Central Hospital, Pori, Finland.
4
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
5
Faculty of Information Technology and Communication Sciences, University of Tampere, Tampere, Finland.
6
Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
7
Department of Oncology, Tampere University Hospital, Tampere, Finland.
8
Institute of Biomedicine, University of Turku, Turku, Finland Johanna.Schleutker@utu.fi.
9
Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, Turku, Finland.

Abstract

BACKGROUND:

Identification of genetic prognostic biomarkers, such as germline variants, are urgently needed to choose optimal treatment for metastatic castration-resistant prostate cancer (mCRPC).

PATIENTS AND METHODS:

The prognostic value of anoctamin 7 (ANO7) rs77559646 on docetaxel response was tested in a prospective PROSTY randomized trial and a retrospective Auria Biobank set. The variant rs77559646 was genotyped and its association with progression-free survival (PFS) and overall survival (OS) was tested.

RESULTS:

In comparison with the non-carriers, the variant carriers had longer PFS (p=0.005) and OS (p=0.003) in the PROSTY cohort. In the retrospective cohort, there was a borderline association with PFS (p=0.09), but not in OS (p=0.9). In both cohorts, Cox regression multivariate models revealed that rs77559646 was an independent prognostic factor for favourable PFS.

CONCLUSION:

The rs77559646 was shown to be a prognostic germline biomarker for better response to docetaxel treatments. To our knowledge, this is the first time that a non-coding germline variant has been associated with chemotherapy of mCRPC.

KEYWORDS:

ANO7; CRPC; docetaxel; prostate cancer

PMID:
31570429
DOI:
10.21873/anticanres.13728
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center